Key takeaways:

• The AREDS2 supplement slowed the expansion of geographic atrophy toward the fovea by approximately 55% over 3 years in patients with dry AMD.
• There was little benefit in those with GA in their central vision.

The original Age-Related Eye Diseases Study (AREDS), published in 2001, found that a supplement formulated with antioxidants — including vitamins C, E, and beta-carotene — as well as zinc and copper could slow the progression of intermediate to late-stage AMD. More than a decade later, the AREDS2 trial published in 2013 determined that substituting the antioxidants lutein and zeaxanthin for beta-carotene could not only improve efficacy but also prevent some risks. Neither study examined further benefits once patients progressed to late-stage disease.

New data show the AREDS2 supplement formulation slows the expansion of geographic atrophy toward the central foveal region, potentially preserving central vision in patients with late AMD

Read more:https://www.healio.com/news/optometry/20240718/areds2-supplement-slows-expansion-of-geographic-atrophy-even-in-latestage-amd?utm_source=selligent&utm_medium=email&utm_campaign=news

Source: Healio

The post AREDS2 supplement slows expansion of geographic atrophy, even in late-stage AMD appeared first on Macular Degeneration Association.